Deployment

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

Maestro by Moon Surgical · Catalog entry · 1 source · not yet field-verified